Nelson N. Stone, MD, argues that performing prostate biopsies is beneficial for detecting malignancies and lesions and cannot be replaced by MRI, despite controversies. He describes the transperineal mapping biopsy (TPMB) procedure, the inadequacies of current technology, targeted focal therapy, and future directions in these techniques.
Read More
Dr. J. Curtis Nickel, MD, FRCSC, explains the relationship between acute and chronic inflammation of the prostate and prostate cancer risk, citing data from the REDUCE trial. He also discusses prostate cancer risk factors, including tumor volume, number of positive cores, and prostate atrophy.
Read More
Dr. Laurence Klotz, MD, argues that active surveillance should continue to be a standard of care for prostate cancer, as long as the urological community takes steps to improve screening methods and reduce overdiagnosis.
Read More
Marc B. Garnick, MD, discusses whether or not follicle stimulating hormone (FSH) affects prostate cancer progression and cause adverse effects when used in combination with androgen deprivation therapy (ADT). He presents evidence for both the pro and con sides of this argument.
Read More
Dr. Gerald L. Andriole, MD, reviews the designs, materials, and outcomes of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and The European Randomized Study of Screening for Prostate Cancer (ERSPC). He distinguishes between legitimate concerns and inappropriate criticisms of the trials. Also, he explains what this means for the practice of PSA testing.
Read More